Castle Biosciences Inc (NAS:CSTL)
$ 24.37 0.63 (2.65%) Market Cap: 672.79 Mil Enterprise Value: 458.63 Mil PE Ratio: 0 PB Ratio: 1.67 GF Score: 79/100

Castle Biosciences Inc at Credit Suisse Healthcare Conference Transcript

Nov 09, 2022 / 08:50PM GMT
Release Date Price: $18.08 (-10.14%)
Unidentified Analyst

For our next presentation, we have Castle Biosciences. Representing Castle is Derek Maetzold, CEO. The floor is yours, Derek.

Derek J. Maetzold
Castle Biosciences, Inc. - Founder, CEO, President & Director

Thank you, [Dam]. And thank you, Credit Suisse, for the invitation to come and have a conversation about Castle Biosciences.

So I'm going to run through some top line of our second quarter -- our third quarter earnings release a couple of weeks ago and then move into kind of a broader business conversation where Castle is today and where we think we're going to go tomorrow.

Disclaimer and forward-looking statements. So -- we had an excellent third quarter performance from my perspective. We saw both test report volume and revenue grow 57%, 58%, respectively over the respective quarters in 2021. So nice solid performance from the team in the third quarter.

On an adjusted gross margin perspective, we are coming in at 76.2% for the third quarter, down from 80%, but that really reflects scaling up in terms of test

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot